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ABSTRACT 30 
Mechanisms of magnesium homeostasis in Mycobacterium tuberculosis are poorly 31 
understood. Herein we describe the characterization of a pyrimidinetrione amide 32 
scaffold that disrupts magnesium homeostasis in the pathogen by direct binding to the 33 
CorA Mg2+/Co2+ transporter. Mutations in domains of CorA that are predicted to regulate 34 
the pore opening in response to Mg2+ ions conferred resistance to this scaffold. The 35 
pyrimidinetrione amides were cidal against the pathogen under both actively replicating 36 
as well as non-replicating conditions in vitro and were efficacious against the organism 37 
during macrophage infection. However, the compound lacked efficacy in infected mice 38 
possibly due to limited exposure. Our results indicate that inhibition of Mg2+ homeostasis 39 
by CorA is an attractive target for tuberculosis drug discovery and encourage 40 
identification of improved CorA inhibitors. 41 
  42 
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INTRODUCTION 43 
Short-course chemotherapy for tuberculosis was adopted by the WHO in 1991 for drug-44 
sensitive disease; requiring 6 months of multi-drug treatment(1). The risk of drug-related 45 
toxicity as well as non-compliance increases proportionally over time which has 46 
motivated efforts to reduce the treatment duration(2). The current front-line drug 47 
regimen consists of drugs that target RNA synthesis (rifampicin), cell wall biosynthesis 48 
(isoniazid/ ethambutol) and pyrazinamide (which has an ill-defined mechanism of 49 
action) (3, 4). Identification of drugs that target novel pathways in the pathogen has 50 
been proposed as a way of developing new drug combinations that could reduce 51 
treatment duration(5). To this end, mechanisms that are critical for survival under 52 
various growth conditions are predicted to encompass targets that could lead to a rapid 53 
decline in bacterial viability in vivo. 54 
Magnesium is an essential co-factor in a plethora of enzymatic reactions. It 55 
serves a structural role in the integrity of nucleic acids and proteins as well as 56 
maintaining the integrity of the cell membrane and cell wall(6, 7). In M. tuberculosis (Mtb) 57 
three mutants have been described that exhibited attenuation at low extracellular 58 
magnesium concentrations: perM encoding a membrane protein of unknown function, 59 
deletion of which results in in vivo attenuation and inability to grow at low Mg2+ 60 
concentrations; phoP encoding the transcriptional regulator of a two-component system 61 
important for complex lipid biosynthesis and virulence; and mgtC which encodes a P-62 
type ATPase likely acting as an accessory protein for Mg2+ importdeletion of which 63 
results in an inability to grow at low Mg2+ concentrations at acidic pH and loss of 64 
virulence(8-10).  The in vivo attenuation of these mutants in Mtb, as well as other 65 
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bacterial pathogens with inactivated Mg2+-dependent processes, has been 66 
hypothesized to point to restriction of this essential cation, as a possibly host-mediated 67 
mechanism to control bacterial pathogens(7-10). Indeed, phagosomal Mg2+ 68 
concentrations at least during Salmonella typhimurium infection have been estimated to 69 
be in the 10-50 micromolar range(11). The predicted low phagosomal Mg2+ 70 
concentrations and the increased Mg2+ requirement of Mtb at low pH, suggests that 71 
access to this nutrient could be growth-limiting in vivo. Consequentially inhibitors of 72 
Mg2+  homeostasis would affect bacterial survival at every stage of host 73 
pathogenesis(12). The mechanisms by which Mtb maintains Mg2+ homeostasis are 74 
poorly understood.  Mtb encodes two Mg2+  transporters, CorA and MgtE, neither of 75 
which is apparently essential based on saturating genome transposon mutagenesis 76 
studies(13, 14).  77 
In this work, we describe the identification of a compound series that exerts 78 
potent growth inhibition of Mtb and inhibits Mg2+ uptake via direct binding to the CorA 79 
transporter. A representative of this inhibitor series lacked in vivo efficacy against Mtb in 80 
mice.  This was presumed to be related to insufficient compound exposure in vivo.  81 
 82 
RESULTS 83 
Identification of a pyrimidinetrione amide with Gram-positive antibacterial activity 84 
This series, as represented by Compound 1 was identified from a large whole cell 85 
phenotypic screen against Mtb and found to have potent antimycobacterial activity on 86 
two distinct growth media (Table 1). The pyrimidinetrione amide core is based on 87 
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barbituric acid. In order to establish some preliminary structure activity relationship 88 
(SAR) analogues were prepared with different amines including a simple aniline (2), 89 
cyclohexylamine (3), butylamine (4), benzylamine (5), 3-picolylamine (6). Except for 90 
compound 2, none showed equivalent antimicrobial activities in both media (Table 1). 91 
Although compound 5 showed good potency in GAST medium (a minimal medium 92 
lacking BSA), the lack of potency in 7H9 medium suggested high protein binding 93 
discouraging further evaluation. The modification of the amide linker to generate either a 94 
sulfonylamine (7) or a ketone (8) also resulted in complete loss of antitubercular activity.   95 
 Based on the initial SAR described in Table 1, a series of compounds modified in 96 
the aniline moiety were further evaluated (Table 2). Interestingly, irrespective of the 97 
substituents in the para-position of the aniline, compounds 914 showed good 98 
antitubercular activities. Compounds 15 & 16 which had a substituent in the ortho-99 
position also showed activity.  While other analogues with heteroaromatic rings instead 100 
of a phenyl groups, such as pyridine (1719) and isoxazole (20), generally had reduced 101 
potency.  Because the core is related to barbituric acid, we wanted to rule out non-102 
specific effects due to mitochondrial membrane depolarization(17). We tested for 103 
cytotoxicity against HepG2 cells during growth on either glucose or galactose as sole 104 
carbon source. Growth on galactose forces cells to use mitochondrial respiration to 105 
generate ATP rather than through glycolysis as occurs during growth on glucose(18). 106 
This showed that several of the compounds were associated with clear mitochondrial 107 
toxicity; evidenced by the enhanced cytotoxicity of compounds during growth on 108 
galactose. Cytotoxicity in galactose medium generally tracked with anti-mycobacterial 109 
potency (Fig. S1). However, compounds having electron donating alkyl groups, methyl 110 
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(9) and isopropyl (10), were both selective and had no mitochondrial toxicity based on a 111 
lack of inhibition of  HepG2 cell growth on either glucose or galactose.,  112 
The compound series was not selectively anti-tubercular as seen by its broader-113 
spectrum activity against Mycobacterium smegmatis, Bacillus subtilis and 114 
Staphylococcus aureus (Table S1). However, the series lacked activity against Gram-115 
negative bacteria such as Escherichia coli and Pseudomonas aeruginosa (data not 116 
shown), suggesting a mechanism of action unique to Gram positive bacteria. 117 
 118 
The pyrimidinetrione amide inhibits magnesium uptake in Mtb 119 
In an effort to understand the mechanism of action of the series, resistant mutants were 120 
raised to compound 1. Mutants were obtained at a frequency of resistance of 10-8. 121 
Three that were confirmed to be more than 100-fold resistant to the compound, were 122 
submitted for whole genome sequencing. Two had independent mutations in corA 123 
(Rv1239c), corA:E212D and corA:A317S, other single nucleotide polymorphisms 124 
present showed no evidence of mechanism of action associated resistance   (Table 3). 125 
The third mutant had an identical SNP profile to the second mutant suggesting that this 126 
mutant may have arisen as a sibling.  127 
The corA gene encodes a putative magnesium and cobalt transporter predicted 128 
to be non-essential by genome-wide transposon mutagenesis studies(13, 14). To 129 
confirm that SNPs in corA were associated with resistance, we raised resistant strains 130 
to compounds (1, 10, 12, 13 & 15) and specifically sequenced their corA gene. All 131 
resistant strains contained point mutations within the corA gene (Table S2). To interpret 132 
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the effect of these mutations on corA function, a MtCorA homology model was 133 
generated from the crystal structure of Thermotoga maritana CorA (TmCorA) using 134 
Phyre2(20). Unexpectedly the mutations did not occur at the divalent cation sensor 135 
region where Mg2+ ions bind. Instead,  the homology model predicted that the mutations 136 
occurred within the acidic (E212D) and kink (G299S & M300V/L) regions which are 137 
involved in the gating motion of CorA; and the hydrophobic tunnel (A317S) where Mg2+ 138 
ions flow through (Fig. S2). The mutation data suggested that the pyrimidinetrione 139 
amide scaffold affected the gating mechanism of CorA resulting in the inhibition of Mg2+ 140 
uptake (Fig. S2).  This hypothesis was supported by the Mg2+ dependence of the growth 141 
inhibition in Mtb (Fig. 1A) as well as other Gram-positive bacteria (Table S2)  142 
Co2+ was unable to rescue cells from pyrimidinetrione-dependent growth 143 
inhibition (Fig. 1B). The inability of Co2+ to rescue growth inhibition was not surprising 144 
since there are no known essential cobalt-dependent enzymes in Mtb. Magnesium is an 145 
essential metal cofactor in many key metabolic enzymes and the specificity of some of 146 
the pyrimidinetrione amides for inhibiting bacterial growth and not HepG2 cell growth 147 
suggested that magnesium uptake could be a novel target for drug development.  148 
To confirm that the series inhibited Mg2+ uptake, intracellular concentrations of 149 
this cation were measured by inductively-coupled plasma mass spectrometry (ICP-MS). 150 
This analysis confirmed that compound 10 treatment generated a concentration-151 
dependent decrease in intracellular magnesium levels (Fig. 1C). Moxifloxacin was 152 
chosen as a negative control because it was not expected to affect cell wall or 153 
membrane integrity both of which could potentially influence intracellular Mg2+ levels. 154 
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However,  moxifloxacin resulted in an unexpected increase in intracellular magnesium 155 
concentrations (Fig. 1C) for reasons which were not clear.  156 
The pyrimidinetrione amide- Mg2+ complex binds to the CorA transporter  157 
The core of this series shows structural similarity to the pyrimidinedione scaffold 158 
associated with Mg2+ binding in drugs such as Raltegravir(21). To explore whether this 159 
series bound Mg2+ ions, we analyzed the UV-Vis spectral response of compound 10 160 
upon titration with Mg2+ ions. A clear cation dependent decrease in absorbance at 280 161 
nm was seen (Fig. S3). The coordination complex of compound 10 with Mg2+ was 162 
further investigated by NMR studies; based on the splitting pattern of the signals of the 163 
asymmetric pyrimidinetrione moiety, compound 10 forms the enol tautomer when 164 
interacting with Mg2+ (Fig. S4). The coordination of Mg2+ by this scaffold could suggest 165 
that the compounds merely act to deplete free Mg2+ ions with the corA mutations 166 
conferring higher affinity for the Mg2+:6H2O complex. However, arguing against this 167 
notion, in the absence of compound the corA mutants required a 250-fold higher Mg2+ 168 
concentration to grow compared to the wild-type strain (Table S3).  169 
In order to test whether the Mg2+:pyrimidinetrione amide complex directly bound to 170 
CorA, we determined the thermal stability of recombinantly expressed CorA in the 171 
presence of Mg2+ and compound 10  (Fig. 2). This showed that all of these ligands 172 
increased thermal stability of the protein, indicating binding to the transporter (Fig. 2, 173 
Table 4). The apparent dissociation constant of CorA with metal ions and compound 10 174 
was determined using fluorescence change based on tryptophan quenching (Fig. S5 175 
and Table 5). The results indicated that Co2+ was poorly bound to CorA compared to 176 
Mg2+ whereas compound 10 bound with a 2-fold higher affinity than Mg2+ alone, 177 
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irrespective of the presence of Mg2+. Although this result showed that 178 
Mg2+:pyrimidinetrione amide complex bound and stabilized the CorA structure, it was 179 
still unclear how this event affected intracellular Mg2+ homeostasis, resulting in 180 
bactericidality. We predicted that mutant strains such as corA:E212D could survive 181 
exposure to compound 10 as a result of lower binding affinity of the CorA:E212D protein 182 
to the Mg2+:compound 10 complex,  hereby overcoming the disruption of Mg2+ 183 
homeostasis. Therefore, we performed similar thermal stability assays and fluorescence 184 
shift assays using one of the mutant CorA proteins, the purified recombinant 185 
CorA:E212, in the presence of Mg2+, compound 10 or compound 10 with Mg2+. The 186 
assay result showed that the Mg2+:pyrimidinetrione amide complex could also bind to 187 
the mutated CorA:E212D (Table S4 and S5). This result suggested that the observed 188 
mutations on CorA do not have a measurable effect on the binding affinity of the 189 
Mg2+:pyrimidinetrione amide complex to this transporter (bearing in mind the limited 190 
analytical sensitivity of these assays).  191 
The pyrimidinetrione amide decreases Mtb viability in vitro and ex vivo but lacks 192 
apparent in vivo efficacy 193 
The pyrimidinetrione amide compound 10 was cidal against actively growing Mtb cells 194 
showing a 2-log kill over a week of exposure even at concentrations as low as 2-fold the 195 
MIC value. Higher concentrations resulted in a more rapid cidal effect with no detectable 196 
viable cells remaining as determined by colony counts on solid agar (Fig. 3A). We next 197 
sought to interrogate the importance of Mg2+ uptake under non-replicating conditions 198 
using a non-replicating persistence induced by adaptation to hypoxia with subsequent 199 
exposure of cells to compounds under anaerobic conditions. This showed that Mg2+ 200 
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uptake was critical under these conditions as evidenced by the greater than 3-log kill 201 
after a week of compound exposure (Fig. 3B). 202 
The cidal consequence of disrupting Mg2+ homeostasis during active growth as 203 
well as non-replicating persistence prompted us to explore their anti-tubercular effect 204 
during parasitism of host macrophages. We selected compounds that had no general 205 
cytotoxic or mitochondrial toxic effect (compounds 9 and 10), no general cytotoxic yet 206 
with a limited mitochondrial toxicity giving a 10-fold selectivity window (compound 16) or 207 
with limited general cytotoxicity and higher mitochondrial toxicity that still gave us a 208 
higher than 10-fold selectivity window (compound 1) (Table 1). All of these compounds 209 
exerted time- and dose-dependent intracellular (ex vivo) killing of Mtb growing in 210 
macrophages (Fig. 3C). 211 
The promising activity of compound 10 against Mtb during growth in 212 
macrophages encouraged us to explore its in vivo efficacy. Preliminary phamacokinetic 213 
(PK) analysis indicated the half-life of compound 10 was 2.5 h  0.4 when dosed once 214 
daily indicating that at least twice per day (BID) dosing was needed. Unfortunately, this 215 
compound was intolerable to mice at high (100 mg/kg) doses. At 30 mg/kg, dosed BID 216 
by oral gavage, the compound  achieved an AUC of 56 g*h/mL which gave a AUC/MIC 217 
ratio of 250 and plasma concentrations that were almost 10-fold above MIC 218 
concentrations at the first trough and just above MIC at 24h  (0.3 g/mL  0.16 SD; Fig. 219 
4A). This dosing schedule was tolerable in naïve mice. Subsequently, Mtb-infected mice 220 
were treated with 30 or 15 mg/kg BID, however, after multiple BID doses, 30 mg/kg was 221 
intolerable to the infected mice necessitating a deescalation to 30 mg/kg once per day 222 
for that group for the remaining dosing period. Due to adverse effects, compound 10 223 
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could not be administered at higher concentrations and at the highest tolerable 224 
concentration, it lacked efficacy after 2 and 4 weeks of treatment in infected mice lungs 225 
(Fig. 4B) and spleens (results not shown).  226 
DISCUSSION 227 
We have identified a pyrimidinetrione amide scaffold with potent in vitro activity against 228 
Mtb. Resistant mutants mapped to the CorA transporter with Mg2+ supplementation 229 
abrogating the growth inhibition in a concentration-dependent fashion. Using 230 
thermostability assays and fluorescence shift  assays, we were able to demonstrate that 231 
this inhibitor binds to CorA in the presence and absence of Mg2+. The ligand binding site 232 
for this inhibitor remains to be identified but we were also able to show that resistance-233 
conferring amino acid mutations had no effect on this ligand binding. Instead, the 234 
mutations mapped to the acidic and kink regions of the cytoplasmic domain of the CorA 235 
transporter which are involved in the gating motion of the pore, indicating that mode of 236 
resistance were not due to changes in CorA-ligand interaction, but likely as a result of 237 
perturbation of the gating motion in response to Mg2+  dissociation from the protein. Low 238 
cytosolic Mg2+  concentrations result in cation dissociation with resultant channel 239 
opening driven by this gating mechanism. In line with a loss of regulation of the pore 240 
opening of the cation channel, the corA:E212D and corA:A317 mutants required a 250-241 
fold higher Mg2+ concentration in the medium than parental wild-type cells for growth 242 
(results not shown). During preparation of this manuscript, a report was published that 243 
found similar mutations in CorA to a pyrimidinetrione as well as 4-hydroxyquinoline 244 
scaffold(19). These mutations were predicted to result in channel opening thereby 245 
resulting in increased cytosolic Mg2+  concentrations. Similar to our work, cytosolic 246 
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concentrations of both free and bound Mg2+  were decreased complementing our data 247 
that these inhibitors directly influence the influx/efflux of this cation. 248 
The observation that the metabolic consequence of CorA inhibition is both growth arrest 249 
and death was surprising since there is an alternative Mg2+  transporter encoded by 250 
mgtE in the bacterium. The finding that only mutations in corA could confer resistance 251 
suggests that regulation of Mg2+ homeostasis by this cation is predominantly conferred 252 
by the CorA transporter where changes in MgtE levels do not occur rapidly enough to 253 
overcome this dysregulation of Mg2+ homeostasis. In contrast, during genetic 254 
inactivation of corA, compensatory genetic changes could occur to alter levels of MgtE 255 
as cells are gradually depleted of CorA protein. The finding that corA but not mgtC or 256 
mgtE is conserved in Mycobacterium leprae, a mycobacterium with a minimal genome, 257 
points to the conserved nature of  Mg2+  homeostasis by this transporter. Despite this, 258 
there is no evidence for the in vivo essentiality of Mtb corA during mouse 259 
pathogenesis(22). Intriguingly, these compounds were only active against Gram positive 260 
bacteria tested and not Gram negatives. CorA is widely distributed in bacteria including 261 
E. coli and P. aeruginosa(6). Lack of activity against these Gram negative microbes 262 
could be due to lack of binding to their CorA counterpart, different mechanisms of Mg2+ 263 
homeostasis, lack of transport of the pyrimidinetrione amides across the outer 264 
membrane or their efflux by multidrug efflux pumps. 265 
Our results emphasize the importance of Mg2+ homeostasis during active 266 
replication as well as non-replicating persistence in vitro and also during parasitism of 267 
host macrophages. Free Mg2+ concentrations in the lung were determined to be 0.67 ± 268 
0.08 mM (data not shown), a value similar to reported concentrations in plasma(23), 269 
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which is below the level that overcomes the growth inhibition by the pyrimidinetrione 270 
amides. The lack of in vivo efficacy was disappointing although the pharmacokinetic 271 
studies suggested that blood serum concentrations were only sufficiently above the MIC 272 
for half of the dosing period when extrapolated from the PK parameters (Fig. 4A). The 273 
concentration of compound in the cellular lesions may further be well below the MIC 274 
level during this dosing period. In addition, despite the lack of cytotoxicity of the 275 
compound, clinical signs of toxicity were evident when mice were dosed at 100 mg/kg 276 
(results not shown) prohibiting additional studies to probe the in vivo efficacy of this 277 
compound.  278 
In conclusion, our results demonstrate the critical role of CorA in maintaining 279 
Mg2+ homeostasis and its attractiveness as a drug target. Despite the in vitro and ex 280 
vivo efficacy of the pyrimidinetrione amides, our data suggests that an alternative 281 
scaffold that inhibits CorA function would need to be identified in order to perform the 282 
proof of concept experiments that establish the validity of this target in vivo. 283 
 284 
MATERIALS AND METHODS 285 
Chemistry.  All chemicals and reagents were purchased from Aldrich (Sigma Aldrich, St. 286 
Louis, MO, USA), Lancaster (Alfa Aesar, Johnson Matthey Company, Ward Hill, MA, 287 
USA) and were used without further purification. Comercially available analogues of 288 
pyrimidinetrione amide were purchased from Enamine LLC (NJ, USA), Bionet America, 289 
Inc. (CA, USA), and MicroCombiChem GmbH (Wiesbaden, Germany). Reactions were 290 
monitored by TLC, performed on silica gel glass plates containing 60 GF-254, and 291 
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visualization on TLC was achieved by UV light or iodine indicator. Column 292 
chromatography was performed with Merck (60-120) mesh silica gel. 1H NMR spectra 293 
were recorded on Varian Mercury-300 NMR Spectrometer and chemical shifts are 294 
reported in ppm downfield from internal TMS standard. Routine mass analyses (LRMS) 295 
were performed on HP Agilent LC/MS series 1100 system equipped with a reverse 296 
phase column (Agilent Poroshell 120 EC-C18, 2.7 μm, 50  2.1 mm) and photodiode 297 
array detector using electrospray ionization (ESI). All the reported compounds were 298 
pure and > 95%. 299 
Synthesis of compound 12, 1420(24) 300 
To a solution of 1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (1.0 eq) in DCM (0.1 M) 301 
was added pyridine (1.2 eq) and 4-dimethylaminopyridine (0.1 eq) at 0°C. 302 
Ethylcarbonochloridate (1.0 eq) was added dropwise to the reaction mixture at the same 303 
temperature over 1h. After stirring for 12 h  at 0°C, the reaction mixture was allowed to 304 
warm to room temperature and then diluted with DCM and washed with water. The 305 
organic layer was dried over Na2SO4 and evaporated in vacuo. The crude mixture was 306 
recrystallized from ethanol to get ethyl 1,3-dimethyl-2,4,6-trioxohexahydropyrimidine-5-307 
carboxylate as a white solid (1.09 g, 75%). 1H NMR (DMSO-d6, 300 MHz)  4.28 (qt, J = 308 
6.9 Hz, 2H), 3.16 (s, 3H), 1.271.23 (t, J = 6.9 Hz, 3H); LCMS (ESI) m/z  229 [M+H]+. 309 
To a solution of ethyl 1,3-dimethyl-2,4,6-trioxohexahydropyrimidine-5-carboxylate (1.0 310 
eq) in toluene (0.5 M) was added each amine (1.0 eq)  and TEA (1.2 eq). The reaction 311 
mixture was refluxed for about 12 h. After cooling down to room temperature, the 312 
reaction mixture was diluted with ethyl acetate and then washed with water. The organic 313 
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layer was dried over Na2SO4 and evaporated in vacuo. The crude mixture was 314 
recrystallized from acetonitrile to get the desired products, 12, 1420. 315 
1,3-Dimethyl-2,4,6-trioxo-N-(4-phenoxyphenyl)hexahydropyrimidine-5carboxamide (12). 316 
White solid (75%):  1HNMR (CDCl3, 300 MHz)  11.92 (s, 1H), 7.46 (d, J = 6.9 Hz, 2H), 317 
7.35 (t, J = 7.2 Hz, 2H), 7.12 (t, J = 7.5 Hz, 1H), 7.037.00 (m, 4H), 3.41 (s, 3H), 3.38 318 
(s, 3H); LCMS (ESI) m/z  368 [M+H]+. 319 
N-(4-acetylphenyl)-1,3-dimethyl-2,4,6trioxohexahydropyrimidine-5-carboxamide (14). 320 
White solid (79%):  1HNMR (CDCl3, 300 MHz)  12.10 (s, 1H), 7.97 (d, J = 8.7 Hz, 2H), 321 
7.63 (d, J = 8.7 Hz, 2H),  3.41 (s, 3H), 3.37 (s, 3H), 2.59 (s, 3H); LCMS (ESI) m/z  318 322 
[M+H]+. 323 
N-(4-bromo-2-fluorophenyl)-1,3-dimethyl-2,4,6-trioxohexahydropyrimidine-5-324 
carboxamide (15). White solid (46%):  1HNMR (CDCl3, 300 MHz)  12.04 (s, 1H), 7.98 325 
(t, J = 8.5 Hz, 1H), 7.387.26 (m, 2H), 3.42 (s, 3H), 3.38 (s, 3H); LC-MS: LCMS (ESI) 326 
m/z  370 [M-H]-. 327 
1,3-Dimethyl-2,4,6-trioxo-N-(2,4,6-trichlorophenyl)hexahydropyrimidine-5-carboxamide 328 
(16). White solid (48%):  1HNMR (CDCl3, 300 MHz)  11.35 (s, 1H), 7.44 (s, 2H), 3.40 329 
(s, 3H), 3.39 (s, 3H); LCMS (ESI) m/z  378 [M+H]+. 330 
N-(6-chloropyridin-3-yl)-1,3-dimethyl-2,4,6trioxohexahydropyrimidine-5-carboxamide 331 
(17). White solid (88%):  1HNMR (CDCl3, 300 MHz)  11.94 (s, 1H), 8.52 (d, , J = 2.4 332 
Hz, 1H) 8.017.96 (dd, J = 2.7 and 8.7 Hz , 1H), 7.35 (d, J = 8.4 Hz, 1H), 3.41 (s, 3H), 333 
3.37 (s, 3H); LCMS (ESI) m/z  311 [M+H]+. 334 
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1,3-dimethyl-N-(6-methylpyridin-2-yl)-2,4,6-trioxohexahydropyrimidine-5-carboxamide 335 
(18). White solid (71%): 1HNMR (CDCl3, 300 MHz)  12.13 (s, 1H), 7.70 (d, J = 7 Hz, 336 
1H), 7.63 (t, J = 7.8 Hz, 1H), 6.98 (d, J = 7.5 Hz, 1H), 3.39 (s, 6H), 2.50 (s, 3H); LCMS 337 
(ESI) m/z  291 [M+H]+. 338 
1,3-Dimethyl-2,4,6-trioxo-N-(4(trifluoromethyl)pyridin-2-yl)hexahydropyrimidine-5-339 
carboxamide) (19). White solid (73%):  1HNMR (CDCl3, 300 MHz)  12.18 (s, 1H), 8.55 340 
(d, J = 5.1 Hz, 1H), 8.27 (s, 1H), 7.32 (d, J = 4.8 Hz, 1H), 3.43 (s, 3H), 3.39 (s, 3H); 341 
LCMS (ESI) m/z  345 [M+H]+. 342 
1,3-Dimethyl-N-(5-methylisoxazol-3-yl)-2,4,6-trioxohexahydropyrimidine-5-carboxamide 343 
(20). White solid (69%): 1HNMR (CDCl3, 300 MHz)  12.04 (s, 1H), 6.52 (s, 1H), 3.41 (s, 344 
3H), 3.36 (s, 3H), 2.43 (s,3H); 13C NMR (CDCl3, 75 MHz)  169.1, 167.8, 162.8, 161.7, 345 
158.4, 91.7, 81.6, 28.5, 12.1; LCMS (ESI) m/z  281 [M+H]+. 346 
Strains, media, and materials. Mtb H37Rv (ATCC 27294) was used for all experiments. 347 
To determine the antimicrobial spectrum of the compounds, B. subtilis and S. aureus 348 
was used as gram positive strains, E. coli and P. aeruginosa were used as gram 349 
negative strains. For liquid cultures, Mtb was grown in 7H9 medium which consists of 350 
Middlebrook 7H9 (Becton Dickinson) broth base supplemented with ADC [albumin 351 
(50 g/L)/dextrose (20 g/L)/NaCl (8.1 g/L)], 0.2% glycerol] and 0.05% Tween 80. Solid 352 
agar media (7H11/OADC) for Mtb growth consisted of Middlebrook 7H11 (Becton 353 
Dickinson) agar base supplemented with OADC [ADC with 0.06% oleic acid]. GAST 354 
(glycerol-alanine-salts-Tween 80) was used as defined minimal liquid growth media for 355 
Mtb(25). Mg2+-free GAST media made by omitting MgCl2:6H2O from the medium 356 
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composition. The low pH nitrosative stress medium contained bovine serum albumin 357 
fraction V (5 g/L)/butyric acid (2.5 mM)/NaNO2 (6.9 mg/mL)/NaCl (0.81 g/L)/0.05% 358 
Tyloxapol, pH adjusted to 6.0. MIC determination was performed as previously 359 
described(25). Luria-Bertani (LB) broth (Difco, New Jersey, USA) was used for MIC of 360 
Gram positive and negative strains. The screening conditions under which the original 361 
pyrimidinetrione hits were identified have been previously described but in brief 362 
consisted of 7H9 medium with readout of Mtb growth after 3 days of compound 363 
exposure(26).  364 
Generation and characterization of pyrimidinetrione resistant mutants.To generate 365 
spontaneously resistant mutants to the compounds, 50 ml of Mtb was grown to OD650nm 366 
0.2. Harvested cells were resuspended in 500 µL of media and 100 µL aliquots (109 367 
cells) plated on 7H11/OADC containing compound 1 at concentrations corresponding to 368 
5x, 10x, 20x MIC. Appropriate dilutions of the cell suspensions were also plated on 369 
drug-free plates to calculate bacterial numbers in the suspensions for determination of 370 
frequencies (resistance frequency being the number of resistant mutants obtained per 371 
number of bacteria plated). Agar plates were incubated at 37°C for 4 weeks. After 4 372 
weeks, 4 colonies growing on 7H11/OADC containing 10x MIC compound 1 were 373 
inoculated in 7H9 media and resistance confirmed by MIC determination. Genomic DNA 374 
of mutants was isolated by the CTAB method(27). Whole genome sequencing was 375 
performed and analyzed as described(28). 376 
Cytotoxicity in HepG2 cells. Cytotoxicity in HepG2 cells was measured by CellTiter-377 
GloTM Luminescent Cell Viability Assay (Promega). For glucose media, 20,000 HepG2 378 
cells were seeded in 96 well white flat-bottom plates (Corning incorporated) in DMEM 379 
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GlutaMAX (Gibco) supplemented with 10% fetal bovine serum, 20 mM HEPES, and 0.5 380 
mM sodium pyruvate. For galactose media, HepG2 cells were pre-cultured in galactose 381 
DMEM and seeded in same plate with glucose media. Galactose DMEM consists of 382 
glucose-free DMEM (Gibco) supplemented with 10% fetal bovine serum, 10 mM D-383 
galactose, 2 mM L-glutamine, 5 mM HEPES, and 0.5 mM sodium pyruvate. The plates 384 
were incubated at 37C with 5% CO2. The following day, 2-fold serial dilutions of 385 
compound up to 100 µM were added in the respective growth medium in duplicate and 386 
cells incubated for 24 hours. After this, 20 µL of CellTiter-glo reagent was added to each 387 
well followed by incubation at 37C with 5% CO2 for 10 min. Cytotoxicity was 388 
determined by measuring luminescence using Fluostar Optima FL (BMG Labtech).   389 
In Silico Analysis. Amino acid sequence of MtCorA (Rv1239c) was retrieved from 390 
Mycobrowser database (https://mycobrowser.epfl.ch/). FASTA format of MtCorA protein 391 
sequence was submitted to PHYRE2 protein fold recognition server. Ninty nine 392 
sequence alignment hits were obtained. The sequence of TmCorA was selected as a 393 
single highest scoring template and 332 residues (91% of MtCorA sequence) were 394 
modelled with 100% confidence by the structure of TmCorA.  395 
Magnesium and cobalt concentration dependent MIC. We used Mg2+-free GAST media 396 
to test the magnesium-dependence of the MIC of the compounds. Two-fold 397 
concentrated GAST generated without the addition of magnesium chloride hexahydrate 398 
was prepared. An equal volume of magnesium chloride in sterile distilled water was 399 
added to the GAST medium to give final concentrations ranging from 0.12 mM up to 400 
240 mM. MIC determinations for the compounds were set up in duplicate as previously 401 
described for each MgCl2 concentration(29). Briefly, an equal volume of medium (50 µL 402 
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GAST at the defined MgCl2 concentration) with compound serially diluted in duplicate 403 
from 50 to 0.024 µM was added to wells of a round-bottom 96-well plate (Nunclon). Mtb 404 
culture in GAST at OD650nm of 0.2 was diluted 1: 500 in 2x Mg
2+-free GAST and 50 µL  405 
added to each well of the 96 well plates. Plates were incubated under 5% of CO2 at 406 
37C. Growth was measured using an inverted enlarging mirror at 1, 2 and 3 weeks with 407 
MIC taken as the concentration that completely inhibited all visible growth. For cobalt 408 
dependent MIC test, CoCl2 was added in GAST media from 0.001 to 5 mM 409 
concentration and MIC performed as above. 410 
Magnesium concentration measurement by inductively coupled plasma - mass 411 
spectroscopy (ICP-MS). We measured magnesium concentrations in Mtb cells treated 412 
by inductively coupled plasma - mass spectroscopy (ICP-MS). Two liters of Mtb was 413 
grown to OD650nm 0.6 in 7H9. Five hundred milliliter of culture volumes were incubated 414 
with 1x, 10x MIC of compound 10, 10x MIC of moxifloxacin or an equivalent volume of 415 
DMSO vehicle control (0.1% v/v) for 24 hours in 2 L capacity rolling bottles. Cells were 416 
harvested and washed three times with 1/10 volume phosphate buffered saline 417 
containing 0.05% Tween 80 (PBST). The wet weight of Mtb cell pellets was recorded to 418 
normalize magnesium concentration prior to autoclaving. ICP-MS analysis was serviced 419 
by Elementary Analysis Inc. (Lexington, KY, USA)  420 
UV spectrum scanning to test magnesium binding of pyrimidinetrione. One milliliter of 421 
100 µM 10 dissolved in 100 mM HEPES buffer was filled in 1 cm path length quartz 422 
crystal cuvettes for UV scanning. The absorbance of the compound 10 solution was 423 
scanned from 200 nm to 400 nm wavelengths by a Varian Cary 300 Bio UV/VIS 424 
spectrophotometer. We sequentially added 10 µL of 1 mM MgSO4 to the compound 425 
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solution to observe changes in absorbance spectrum. A standard curve was plotted with 426 
A280nm of 5, 10, 50 and 100 µM of compound 10. Absorbance at 280 nm was used to 427 
calculate compound 10 after correcting for changes in volume and plotted in a graph.  428 
Minimum magnesium requirement test. Mtb H37Rv, corA:E21D, and corA:A317S 429 
strains were cultured in GAST to OD650nm 0.2 at 37°C.  Fifty microliter of Mg
2+-free 430 
GAST was distributed in every well of a round-bottom 96-well plate (Nunclon).  Fifty L 431 
of 240 mM of MgCl2 dissolved in Mg
2+-free GAST was added to the wells of the first 432 
column of this plate and 50 L volumes transferred from column 1 to column 12 433 
generating a 2-fold serial dilution series of MgCl2 across the plate. Mtb cultures were 434 
diluted 1: 500 in Mg2+-free GAST and 50 µL added to each well of the 96 well plates. 435 
Growth was measured using an inverted enlarging mirror at 1, 2 and 3 weeks with the 436 
minimum Mg2+ concentration to support growth taken as the lowest concentration that 437 
supported evidence of any visible growth.  438 
Cloning, expression and purification of MtCorA. The M. tuberculosis corA gene, 439 
rv1239c, was cloned into the pET28a vector. The gene was amplified by PCR using 440 
Herculase II Fusion DNA polymerase (Agilent) and the following primers: forward-5’-441 
CGCGGCAGCCATATGTTCCCAGGGTTT-3’ and reverse-5’-442 
TGCGGCCGCAAGCTTCTAGAGCCAGTTTCT-3’.The PCR-amplified gene was 443 
inserted between two restriction sites, NdeI and HindIII, using In-Fusion® HD Cloning 444 
Plus (Takara). Site-directed mutagenesis to obtain gene encoding corA:E212D mutant 445 
was performed. MtCorA contained the N-terminal poly-histidine tag. The plasmids 446 
carrying the wildtype and mutant corA gene were transformed into in OverExpress™ 447 
C41(DE3) (Lucigen). The cells were grown in LB media at 37ºC. The induction was 448 
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initiated with 1mM IPTG at OD600nm 0.7-0.8 and after 6 h, the cells were harvested by 449 
centrifugation at 3500 rpm for 20 min. The cell pellet was resuspended in lysis buffer 450 
containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5 mM DTT and SIGMAFAST™ 451 
Protease Inhibitor Cocktail Tablets, EDTA-Free (Sigma-Aldrich). After sonication, the 452 
lysed cells were pelleted by centrifugation at 20,000 g for 60 min and the membrane 453 
was isolated from the supernatant by ultracentrifugation at 142,000 g for 60 min. The 454 
isolated membrane was then solubilized in the resuspension buffer, 50 mM Tris-HCl pH 455 
8.0, 300 mM NaCl, 20 mM imidazole, 0.5 mM DTT, with 1% (w/v) dodecyl maltoside 456 
(DDM) (Anatrace). The resulting supernatant was loaded onto a Ni-NTA column. The 457 
column was washed with wash buffer consisting of 50 mM Tris-HCl pH 8.0, 300 mM 458 
NaCl, 40 mM imidazole, 0.5 mM DTT, with 0.1% (w/v) DDM. The CorA or CorA mutant 459 
protein was eluted with elution buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 300 mM 460 
imidazole, 0.5 mM DTT, with 0.05% (w/v) DDM) and the resulting supernatant fractions 461 
containing CorA were identified using SDS-PAGE, pooled and dialyzed against dialysis 462 
buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.5 mM DTT, with 0.05% (w/v) DDM).The 463 
protein was finally purified on a Superdex 200 16/60 (GE Healthcare) in 50 mM Tris-HCl 464 
pH 8.0, 300 mM NaCl, 0.5 mM DTT, with 0.05% (w/v) DDM. 465 
Thermostability test of CorA with pyrimidinetriones. Purified MtCorA samples were 466 
diluted to a concentration of 0.5 mg/mL. The solution was aliquoted into 30 μl volumes, 467 
with 1 μL of a stock solution of different Mg2+ concentrations added to the aliquot. 468 
Samples were incubated for 20 min at room temperature and then further incubated for 469 
10 min at every increment of 5°C up to 95°C in a thermocycler. The samples were 470 
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transferred to a 96-well filter plate (0.45 μm) (Millipore) to remove precipitated proteins. 471 
The yield of the filtered protein was analyzed by SDS/PAGE. 472 
Substrate Binding Measured by Fluorescence Quenching. The dissociation constants 473 
between CorA and its ligands, Mg2+, Co2+ and compound 10, were determined by the 474 
ligand dose-dependent fluorescence quenching assay (Cary Varian Eclipse 475 
fluorescence spectrophotometer). CorA was titrated with increasing concentrations of 476 
ligands and fluorescence emission was measured at ~350 nm following excitation at 477 
283 nm (bandwidths of 5nm). The fluorescence quenching ΔF versus ligands 478 
concentration [S] was plotted and Kd(app) of CorA to ligands were calculated by fitting 479 
the data to an equation,  480 
ΔF = (F0 − F) =
ΔFmax ∗ [S]
Kd(app) + [S]
   
where F0 and F are the fluorescence intensities in the absence and presence of 481 
substrates, respectively, [S] is the ligand concentration, and Kd(app) is the apparent 482 
dissociation constant of CorA to ligands.  483 
Efficacy study in vitro, ex vivo and in vivo. In vitro efficacy of compounds against Mtb 484 
was measured during aerobic growth as well as during anaerobic non-replicating 485 
persistence. Time kill kinetics were measured under aerobic conditions as follows. 486 
Logarithmically growing Mtb (OD650nm 0.2) was diluted 1,000-fold in 7H9 media and 1 ml 487 
volumes exposed to 1x, 2x, 5x, 10x, and 20 x MIC compound 10 up to 7 days in 488 
duplicates. Samples were collected and plated on 7H11/OADC plates for CFU 489 
enumeration at 1, 2, 4 and 7 days of treatment. For anaerobic conditions, Mtb was 490 
cultured in the self-generated oxygen-depletion model as previously described(29).  491 
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One milliliter volumes of anaerobic Mtb culture was exposed 1 week to 1x, 5x, 10x, 20x 492 
and 50x MIC compounds 9, 10, and 20 in an anaerobic chamber (Microbiology 493 
International) followed by CFU enumeration as above.  494 
For ex vivo efficacy testing, J774 cells (6.6 x 104 cells/well) were seeded in flat-bottom 495 
24 well plates (Corning incorporated) in J774 growth medium consisting of DMEM 496 
GlutaMAX (Gibco) supplemented with 10% fetal bovine serum, 20 mM HEPES + 0.5 497 
mM sodium pyruvate. Mtb H37Rv with confirmed high levels of phthioceral 498 
dimycocerosate was grown in 7H9 to an OD650nm of 0.5, filtered through a 5 m sterile 499 
filter to ensure a single cell suspension, cell density confirmed at OD650nm, and diluted in 500 
J774 growth medium to 4.4 x 105 CFU/mL. Aliquots of 0.1 mL of the Mtb suspension 501 
was added to each well of the 24-well plate giving an MOI 1:1.5. After overnight 502 
incubation, medium was aspirated and monolayers were washed twice in pre-warmed 503 
PBS (pH 7.4) twice. At this point, four wells were used for CFU enumeration as 504 
described below. To the remaining wells, 1mL J774 growth medium containing 505 
compound or vehicle (DMSO) control was added to each well. Each compound was 506 
tested at 1, 5, and 10-fold its MIC concentration in duplicate wells for each time point 507 
and concentration. Rifampicin (0.5 and 5 g/mL) was used as positive control. Cells 508 
were incubated at 37C, 95% humidity, 5% CO2 incubator for 3 and 7 days. Media was 509 
replenished at days 3 and 5 taking care not to remove any macrophages since the 510 
pyrimidinetrione amides resulted in loss of adherence of macrophages over time. After 3 511 
or 7 days of incubation, medium was removed taking care notremove macrophages and 512 
1mL of 7H9 medium containing 0.1% SDS added to each well to ensure macrophage 513 
lysis. After 5 minutes, lysate was rapidly mixed to shear eukaryotic DNA, diluted in 7H9 514 
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and plated on 7H11/OADC plates. Colony counts were enumerated after 4 weeks of 515 
incubation at 37C. 516 
Mouse studies were carried out in accordance with the Guide for the Care and Use of 517 
Laboratory Animals of the National Institutes of Health under Animal study protocol 518 
numbers LCIM 4E. Pharmacokinetic analyses on 20 C57BL/6J mice were done by 519 
administering 30 mg/kg compound 10 suspended in 10% (2-Hydroxypropyl)-β-520 
cyclodextrin with 50 mM tricine (pH 8.2) twice per day (with a separation of 7 hours) by 521 
oral gavage followed by blood sampling at 0.5, 1, 2, 4, 8, 12 and 24 hours.  0.1 mL of 522 
blood was collected twice from each animal over the experiment into Li-Heparin 523 
Microvette tubes (Sardtedt AG & Co; Numbrecht, Germany) and centrifuged to prepare 524 
to plasma.  Tolerability of compound 10 was tested by dosing 5 naïve mice twice per 525 
day with 100 or 30 mg/kg for 7 days with observation for 7 subsequent days. For 526 
evaluation of in vivo efficacy, C57BL/6J mice were infected by the aerosol route as 527 
previously described(30). After 14 days, groups of 10 mice were dosed with compound 528 
10 given by oral gavage of either 15 mg/kg or 30 mg/kg twice a day. The higher dose 529 
group developed signs of distress after 1 week and so that group was dose deescalated 530 
to 30 mg/kg once a day. Control groups were dosed with vehicle control (10% (2-531 
Hydroxypropyl)-β-cyclodextrin) with 50 mM tricine (pH 8.2) or 10 mg/kg Rifampicin. After 532 
2 and 4 weeks of treatment, groups of 5 mice were euthanized and appropriate dilutions 533 
in 7H9 medium of lung and spleen homogenates plated on 7H11/OADC plates for CFU 534 
enumeration.  535 
Pharmacokinetic analysis of pyrimidinetriones. Pharmacokinetic plasma samples were 536 
analyzed by an Agilent 1200 Infinity HPLC with Agilent 6460C Triple quadrupole mass 537 
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selective detector (LC-QqQ) utilizing electrospray ionization (ESI).  Samples were 538 
prepared by mixing 50 µL serum with 50 µL labetalolTM internal standard (IS), 20 µL 539 
water or spike solution, followed by 400 µL acetonitrile/methanol 3:1 for protein 540 
precipitation.  Samples were centrifuged 13 k rpm x 5 min and 5 µL supernatant injected 541 
into a 2.1 x 50 mm EclipsePlus C18 1.8 µm column utilizing aq. 0.1% formic acid 542 
(solvent A) and acetonitrile w 0.1% formic acid (solvent B).  Solvent gradient program 543 
was 8% B hold 0.5 minutes to 95% B in 4.5 minutes with flow rate 0.8 ml/min.   544 
MRM transition for compound 10 was detected as [M-H]- precursor (Q1), CEV 24V, and 545 
155 product ion(Q2) negative mode, and IS detected as M+H+ precursor (Q1), CEV 8V, 546 
and 311.2 product ion (Q2) positive mode.PK prameters were calculated using PK 547 
macros in Excel. 548 
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Mtb, Mycobacterium tuberculosis; Kan, kanamycin; INH, isoniazid; RIF, rifampicin; MIC, 559 
minimum inhibitory concentration; AUC, area under the curve; CFU, colony-forming 560 
units; ICP-MS, inductively-coupled plasma mass spectrometry. 561 
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TABLE 1  Antitubercular activity of pyrimidinetrione amide analogs   655 
Compound
a
 
Chemical Structure 
 
MIC (µM) 
 
 
R  7H9
b
 GAST
c
 
1 
 
 0.2 0.29 
2 
 
 2.24 1.49 
3 
 
 >50 9.4 
4 
 
 25 12.5 
5 
 
 50 0.39 
6 
 
 >50 >50 
7 
 
 >50 37 
8 
 
 >50 >50 
a
 All compound 18 are known molecules. MIC of compound against Mtb H37Rv in 
b 
Middlebrook 7H9/BSA 656 
containing glucose/glycerol/Tween80, 
c
 GAS medium with Tween80. 657 
 658 
  659 
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TABLE 2  Antitubercular activity and cytotoxicity of pyrimidinetrione amide analogs 660 
 661 
Compound
a
 
Chemical Structure  MIC (µM)  Cytotoxicity (IC50, µM) 
R  7H9
b
 GAST
c
 Butyrate
d
 7H9 
(corA:E212D)
e
 
 
Glucose
f
 Galactose
g
 
1 
 
 0.20 0.29 0.10 >50  29.5 5.50 
2 
 
 2.24 1.49 ND ND  ND ND 
9 
 
 1.20 0.78 1.56 >50  >100 >100 
10 
 
 0.59 0.20 3.13 6.25  >100 >100 
11 
 
 3.10 1.56 3.13 3.10  72.5 23.0 
12 
 
 0.78 0.20 0.59 6.25  26.6 3.50 
13 
 
 0.20 0.07 1.17 3.13  24.6 3.80 
14 
 
 3.10 4.69 3.13 25.0  8.54 2.10 
15 
 
 0.78 0.20 1.17 9.38  19.0 5.20 
16 
 
 6.30 1.17 6.25 >50  >100 50 
17 
 
 4.70 3.13 3.13 >50  >100 28.0 
18 
 
 >50 >50 >50 >50  ND ND 
19 
 
 >50 >50 >50 >50  ND ND 
20 
 
 9.38 2.34 50 >50  ND ND 
 
a
 Compound 1, 2, 911, 13 are known molecules. MIC of compounds against Mtb H37Rv in 
b 
Middlebrook 7H9/BSA 662 
containing glucose/glycerol/Tween80, 
c 
GAS medium with Tween80, 
d 
Middlebrook 7H9/BSA/Tyloxapol/butyrate/0.1 663 
mM nitrite/pH 6.0. 
e
 MIC of compounds against CorA:E212D mutant Mtb strain in Middlebrook 7H9/BSA containing 664 
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glucose/glycerol/Tween80. 
f
 Cytotoxicity of compound tested against HepG2 cells in DMEM/10% FBS supplemented 665 
with glucose.
 g
 Cytotoxicity of compound tested against HepG2 cells in DMEM/10% FBS with galactose. 666 
 667 
TABLE 3  Mutations identified in pyrimidinetrione amide-resistant Mtb strains 668 
Strain Polymorphisms 
E2.1 corA:E212D, 4221182:T>C (-30 bp upstream of Rv3776) 
E2.2 corA:A317S, Rv0275c:S233S, 3281706 -G (in aa 342/2111 of mas) 
E2.6 Same as E2.2 
 669 
TABLE 4  Thermostability of CorA in the presence of metal cations, EDTA and compound 10. 670 
CorA + additive Melting temperature (C̊) 
none 55 
0.125 mM MgCl2 70 
1 mM compound 10 ≥95 
1 mM compound 10 / 0.125 mM MgCl2 ≥95 
1 mM EDTA / 0.125 mM MgCl2 ≥95 
 671 
TABLE 5  The apparent dissociation constant (Kd(app)) of CorA with metal cations and 672 
compound 10. 673 
CorA additives in fluorescence shift assay Kd(app) µM 
Mg
2+
 47.5 ± 3.0 
Co
2+
 205 ± 18 
Compound 10 20.0 ± 4.3 
Compound 10  / 1 mM Mg
2+
 24.1 ± 6.3 
Compound 10 / 1 mM Co
2+
 21.8 ± 4.1 
 674 
  675 
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FIGURE LEGENDS 676 
FIG 1 The pyrimidinetrione amide scaffold inhibits Mg2+ uptake by Mtb. (A) Magnesium 677 
dependence of the pyrimidinetrione amide MIC against Mtb performed in Mg2+-free 678 
media with the indicated concentrations of Mg2+. (B) Co2+ dependence of the 679 
pyrimidinetrione amide MIC against Mtb performed in Co2+-free media with the indicated 680 
concentrations of Co2+. (C) Fold change in intracellular Mg2+ concentration as measured 681 
by ICP-MS compared to vehicle (DMSO) control after 24h of treatment with moxifloxacin 682 
(Mox) or compound 10 at 1- or 10-fold MIC concentration in 7H9 medium which 683 
contains 0.4 mM Mg2+. Significance between groups was determined by Tukey’s 684 
Multiple Comparison Test with significance set at P values less than 0.05. 685 
FIG 2  Magnesium and the pyrimidinetrione scaffold bind to the CorA transporter 686 
protein. The thermostability of recombinantly expressed CorA from Mtb was measured 687 
with (A) no ligand, (B) 0.125 mM MgCl2 and (C) 0.125 mM MgCl2 with or without 1.0 mM 688 
compound 10. Protein was pre-incubated at room temperature with the indicated 689 
ligands before heating to the indicated temperatures in a thermocycler. Protein 690 
precipitates were removed by filtration and soluble protein analyzed by SDS-PAGE. 691 
FIG 3 The pyrimidinetrione amide scaffold is cidal against replicating as well as non-692 
replicating Mtb in vitro and ex vivo. (A) Kill kinetics of compound 10 against Mtb during 693 
active replication in vitro as compared to negative (DMSO) and positive (5 µg/mL RIF) 694 
controls. (B) Anaerobic cidal activity of compounds 9, 10 and 20 as compared to 695 
negative (untreated, DMSO and 1 µg/mL INH) and positive (100 µM metronidazole) 696 
controls after 7 days of compound exposure. (C) Efficacy of compounds 1, 9, 10 and 16 697 
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during growth of Mtb in J774 macrophages as compared to the negative (DMSO) and 698 
positive (0.5 and 5 µg/mL RIF) controls. Black horizontal bar indicates inoculum (day 0). 699 
FIG 4  The pyrimidinetrione amide lacks in vivo efficacy. (A) PK profile of compound 10 700 
after twice daily administration at 30 mg/kg. (B) Mtb bacterial burdens in infected mice 701 
after 2 and 4 weeks of once daily or twice daily treatment at 30 and 15 mg/kg, 702 
respectively. Treatment was initiated at 2 weeks after aerosol infection of the mice. 703 
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